Another small step for Chinese R&D as Sihuan molecule heads towards trials
This article was originally published in Scrip
The product itself may not be an innovative breakthrough, but the recent acceptance by China's State FDA of an application by Sihuan Pharmaceutical Holdings to begin domestic clinical trials with a calcium antagonist marks the continued emergence of the country's R&D capabilities.
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.